A recent study reveals that patients who stop using popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt traditional diet and exercise plans.
Research printed in a prominent health publication shows that while overweight individuals frequently drop a large proportion of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Individuals using such treatments must be aware of the danger of quick weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
Such speed of regain implies a return to starting mass in about one and a half years.
Comparing Therapies
The research, which looked at dozens of trials involving over 9,000 of participants, compared the effects of these new drugs with older methods.
Scientists emphasize that people who shed pounds through dieting generally see a more gradual creep back—approximately 0.1 kg a month—once they finish.
The Reason for the Fast Rebound
Doctors believe the mechanism of the jabs accounts for the accelerated weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' means appetite is uncontrolled, making excessive eating a significant risk."
A Chronic Condition?
Health authorities advise the injections for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts contend that, considering the likelihood of weight regain, the treatment is often long-term.
This perspective is supported by drug manufacturers, who say that the results "underscore the long-term character of obesity," similar to managing conditions like diabetes.
Patient Experiences
People who have discontinued the jabs report a intense resurgence of cravings.
"It felt as if something that goes on and you become ravenous," recalled a patient.
This difficulty is worsened if users have not developed lasting dietary or behavioural modifications during therapy.
Growing Use
Survey data show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is higher among women than males.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and long-term success hinges on ongoing lifestyle management.
